Liver-related deaths in persons infected with the human immunodeficiency virus -: The D:A:D study

被引:890
作者
Weber, Rainer [1 ]
机构
[1] Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland
关键词
D O I
10.1001/archinte.166.15.1632
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases. Methods: We investigated the frequency of and risk factors associated with liver-related deaths in the Data Collection on Adverse Events of Anti-HIV Drugs study, which prospectively evaluated 76893 person-years of follow-up in 23441 HIV-infected persons. Multivariable Poisson regression analyses identified factors associated with liver-related, AIDS- related, and other causes of death. Results: There were 1246 deaths ( 5.3%; 1.6 per 100 person-years); 14.5% were from liver-related causes. Of these, 16.9% had active hepatitis B virus ( HBV), 66.1% had hepatitis C virus ( HCV), and 7.1% had dual viral hepatitis coinfections. Predictors of liver-related deaths were latest CD4 cell count ( adjusted relative rate [RR], 16.1; 95% confidence interval [CI], 8.1-31.7 for < 50 vs >= 500/mu L), age ( RR, 1.3; 95% CI, 1.2-1.4 per 5 years older), intravenous drug use ( RR, 2.0; 95% CI, 1.2- 3.4), HCV infection ( RR, 6.7; 95% CI, 4.0-11.2), and active HBV infection ( RR, 3.7; 95% CI, 2.4-5.9). Univariable analyses showed no relationship between cumulative years patients were receiving cART and liver-related death ( RR, 1.00; 95% CI, 0.93-1.07). Adjustment for the most recent CD4 cell count and patient characteristics resulted in an increased risk of liver-related mortality per year of mono or dual antiretroviral therapy before cART ( RR, 1.09; 95% CI, 1.02-1.16; P=.008) and per year of cART ( RR, 1.11; 95% CI, 1.02-1.21; P=.02). Conclusions: Liver-related death was the most frequent cause of non-AIDS-related death. We found a strong association between immunodeficiency and risk of liver related death. Longer follow-up is required to investigate whether clinically significant treatment-associated liver-related mortality will develop.
引用
收藏
页码:1632 / 1641
页数:10
相关论文
共 38 条
[1]
Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: Data from the HIV Atlanta VA Cohort Study [J].
Anderson, KB ;
Guest, JL ;
Rimland, D .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (10) :1507-1513
[2]
Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients [J].
Braitstein, P ;
Yip, B ;
Montessori, V ;
Moore, D ;
Montaner, JSG ;
Hogg, RS .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (02) :160-164
[3]
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[4]
Hepatitis C and liver transplantation [J].
Brown, RS .
NATURE, 2005, 436 (7053) :973-978
[5]
Mortality due to hepatitis C virus-related cirrhosis in patients infected with HIV type 1: A role for alcohol [J].
Cainelli, F ;
Concia, E ;
Vento, S .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1795-1796
[6]
Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[7]
Predictors of patient and graft survival following liver transplantation for hepatitis C [J].
Charlton, M ;
Seaberg, E ;
Wiesner, R ;
Everhart, J ;
Zetterman, R ;
Lake, J ;
Detre, K ;
Hoofnagle, J .
HEPATOLOGY, 1998, 28 (03) :823-830
[8]
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[9]
Combination antiretroviral therapy and the risk of myocardial infarction [J].
Friis-Moller, N ;
Sabin, CA ;
Weber, R ;
Monforte, AD ;
El-Sadr, WM ;
Reiss, P ;
Thiébaut, R ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Lundgren, JD ;
Lundgren, JD ;
Weber, R ;
Monteforte, AD ;
Bartsch, G ;
Reiss, P ;
Dabis, F ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Houyez, F ;
Loeliger, E ;
Tressler, R ;
Weller, I ;
Friis-Moller, N ;
Sabin, CA ;
Sjol, A ;
Lundgren, JD ;
Sawitz, A ;
Rickenbach, M ;
Pezzotti, P ;
Krum, E ;
Meester, R ;
Lavignolle, V ;
Sundström, A ;
Poll, B ;
Fontas, E ;
Torres, F ;
Petoumenos, K ;
Kjær, J ;
Hammer, S ;
Neaton, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003
[10]
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study [J].
Friis-Moller, N ;
Weber, R ;
Reiss, P ;
Thiébaut, R ;
Kirk, O ;
Monforte, AD ;
Pradier, C ;
Morfeldt, L ;
Mateu, S ;
Law, M ;
El-Sadr, W ;
De Wit, S ;
Sabin, CA ;
Phillips, AN ;
Lundgren, JD .
AIDS, 2003, 17 (08) :1179-1193